Diametric Capital LP Increases Holdings in Esperion Therapeutics, Inc. $ESPR

Diametric Capital LP increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 57.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 678,824 shares of the biopharmaceutical company’s stock after purchasing an additional 248,648 shares during the quarter. Diametric Capital LP’s holdings in Esperion Therapeutics were worth $668,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Two Seas Capital LP lifted its holdings in Esperion Therapeutics by 43.6% in the 2nd quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock worth $9,800,000 after purchasing an additional 3,024,104 shares in the last quarter. Marshall Wace LLP raised its position in shares of Esperion Therapeutics by 46.2% during the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock valued at $5,206,000 after buying an additional 1,679,294 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Esperion Therapeutics by 3.1% in the second quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock worth $4,513,000 after buying an additional 137,691 shares in the last quarter. Nuveen LLC purchased a new position in shares of Esperion Therapeutics in the first quarter worth $4,446,000. Finally, Wellington Management Group LLP boosted its position in shares of Esperion Therapeutics by 36.0% during the first quarter. Wellington Management Group LLP now owns 761,980 shares of the biopharmaceutical company’s stock worth $1,097,000 after acquiring an additional 201,704 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Analyst Ratings Changes

ESPR has been the topic of a number of research reports. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target on the stock. Wall Street Zen cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Friday, September 19th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Esperion Therapeutics Trading Up 0.3%

Shares of NASDAQ ESPR opened at $3.79 on Friday. Esperion Therapeutics, Inc. has a 12-month low of $0.69 and a 12-month high of $4.03. The firm’s 50-day moving average price is $2.99 and its 200-day moving average price is $2.08. The stock has a market capitalization of $906.04 million, a price-to-earnings ratio of -7.58 and a beta of 1.01.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The business had revenue of $87.31 million during the quarter, compared to the consensus estimate of $78.33 million. On average, equities analysts predict that Esperion Therapeutics, Inc. will post -0.29 EPS for the current fiscal year.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.